Press release | Leiden, 19 March 2020

innoser logo

InnoSer continues to deliver critical in-vivo and in-vitro services

COVID-19 restrictions call for attention to prevent fully halting life sciences operations

InnoSer remains committed to continuing its in-vivo and in-vitro research services in its Leiden and Diepenbeek facilities to help prevent a full interruption of critical research programs – including some with strong links to COVID-19.

Jan Bartels, InnoSer’s CEO, underlines the importance of continued operations: “The life sciences sector, like many others, is being hit by the SARS-CoV-2 outbreak, the containment measures and the illness of key staff. We unfortunately hear that some facilities are already forced to stop their operations. Therefore, we make it our responsibility to implement measures not only for the safety of our staff, customers and other stakeholders, but also of the life sciences sector and society as a whole.”

By implementing certain restrictions, InnoSer aims to ensure safety within the company. Priority is given to critical activities, only required personnel remain in the facilities, and they follow strict procedures on using protective equipment, social distancing and increased attention to hygiene. 

Research programs that are (temporarily) in need of support are invited to contact InnoSer via to discuss available options.


About InnoSer

Founded in 2012, InnoSer is an innovative and dynamic contract research organization (CRO) supporting discovery and preclinical development of drugs. InnoSer’s offerings include PDXO screening platform for oncology, ADPKD mouse model for nephrology, and validated brain organoid models for Parkinson’s for neurodegenerative diseases. It also provides in-vitro pyrogenicity testing and genetically engineered mice model services like colony management, cryopreservation, sanitation/rederivation and pathology.


For more information, please contact: 

Jan Bartels